Merck & Co. (MRK)
(Delayed Data from NYSE)
$103.98 USD
-1.90 (-1.79%)
Updated Oct 25, 2024 04:00 PM ET
Pre-Market: $104.17 +0.19 (0.18%) 9:20 AM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$103.98 USD
-1.90 (-1.79%)
Updated Oct 25, 2024 04:00 PM ET
Pre-Market: $104.17 +0.19 (0.18%) 9:20 AM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.
Merck (MRK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.
Merck (MRK) Stock Moves -1.45%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $78.67, moving -1.45% from the previous trading session.
5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.
Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports third-quarter earnings.
Eiger (EIGR) Up on Positive Results From Coronavirus Study
by Zacks Equity Research
Eiger (EIGR) gains on positive results from the ILIAD study on peginterferon lambda-1a (lambda) in outpatients with mild-to-moderate COVID-19.
Merck's Keytruda Gets FDA Nod for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA approves Merck's (MRK) Keytruda for the treatment of adult patients with relapsed or refractory cHL who progress after frontline therapy.
Pharma Stock Roundup: J&J's Q3 Earnings, Pause on Coronavirus Studies & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q3 estimates for earnings and sales. J&J and Lilly (LLY) pause studies on their coronavirus vaccine and antibody candidates, respectively.
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK
Regeneron's (REGN) Inmazeb Ebola Treatment Gets FDA Approval
by Zacks Equity Research
Regeneron (REGN) gets FDA nod for its triple antibody cocktail for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients.
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Celldex Initiates Early-Stage Antibody Study for Skin Disorder
by Zacks Equity Research
Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.
Do J&J's Q3 Results Indicate a Sales Recovery for Big Pharma?
by Kinjel Shah
Investors typically look at J&J's (JNJ) results for signals regarding how the rest of the big drugmakers will fare.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $80.71, moving +0.44% from the previous trading session.
Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev
by Zacks Equity Research
Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.
J&J (JNJ) Beats on Q3 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
J&J (JNJ) beats third-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.
Bristol Myers (BMY) Gains on Positive Opdivo Data in NSCLC
by Zacks Equity Research
Bristol Myers' (BMY) shares gain as the phase III study evaluating Opdivo plus chemotherapy meets primary endpoint for the indication of NSCLC.
Here's How J&J (JNJ) Will Roll Out Drug Sector Q3 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while the Medical Devices segment might have been hurt by the COVID-19 impact in the third quarter.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $80.04, moving +0.51% from the previous trading session.
Here's Why Small-Cap ETFs Are Hitting New Highs
by Sweta Killa
Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - October 07, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?